We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The transaction will be financed through a combination of cash on hand and a revolving line of credit facility that Bio-Techne expects to obtain prior to the closing of the acquisition.
The partnership with Exosome Diagnostics is part of CareFirst's HealthWorx program, under which the insurance provider works with early-stage companies to accelerate health plan coverage of their products.